MNX1‐AS1 is a novel biomarker for predicting clinical progression and poor prognosis in lung adenocarcinoma

摘要

Abstract Motor neuron and pancreas homeobox 1‐antisense RNA1 (MNX1‐AS1) is a novel long noncoding RNA and has been suggested to be overexpressed in human ovarian cancer and glioma. The role of MNX1‐AS1 in lung cancer was still unknown. In our study, we observed levels of MNX1‐AS1 expression through analyzing The Cancer Genome Atlas and found MNX1‐AS1 expression was highly expressed in lung adenocarcinoma tissues compared with normal lung tissues, but there was no statistical difference between lung squamous cell carcinoma tissues and normal lung tissues. Furthermore, we conducted quantitative real‐time polymerase chain reaction, and confirmed that the expression of MNX1‐AS1 was definitely higher in lung adenocarcinoma tissue samples, but not in lung squamous cell carcinoma tissue samples. In addition, high MNX1‐AS1 expression was found to be associated with the low differentiated degree, advanced clinical stage, big tumor size, lymph node metastasis, and distant metastasis in lung adenocarcinoma patients. High expression of MNX1‐AS1 was negatively correlated with overall survival time and served as an independent unfavorable prognostic factor in patients with lung adenocarcinoma. The in vitro functional studies suggested that suppression of MNX1‐AS1 inhibited lung adenocarcinoma cell proliferation and migration, and promoted apoptosis. In conclusion, MNX1‐AS1 is overexpressed in lung adenocarcinoma, and associated with clinical progression and poor prognosis.